Pharmacological effects of berberine and its derivatives: A patent update

Expert Opinion on Therapeutic Patents

Volumn 26, Issue 2, 2016, Pages 229-243

  Jin, Yifeng ^a   Khadka, Daulat B ^a   Cho, Won Jea ^a  

^a Chonnam National University   (South Korea)

Author keywords

Alzheimer's disease; berberine; cancer; diabetes; inflammation; obesity

Indexed keywords

2,3,4 TRIHYDROXYBENZALDEHYDE 9 O BERBERINE ACYLHYDRAZONE; BERBERINE DERIVATIVE; CISPLATIN; CN 102850346A; CN 102989017B; CN 103127101A; CN 103159755A; CN 103271907A; CN 103284998A; CN 103393679A; DOXORUBICIN; INORGANIC SALT; METFORMIN; PACLITAXEL; PROPIONIC ACID; UNCLASSIFIED DRUG; US 20130237556A 1; BERBERINE;

ALZHEIMER DISEASE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATHEROSCLEROSIS; AUTOPHAGY; CANCER THERAPY; CARDIOVASCULAR DISEASE; CHINESE MEDICINE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CORYDALIS; DIABETES MELLITUS; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; HERBAL MEDICINE; HUMAN; INFLAMMATION; MALARIA; NEOPLASM; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; RHEUMATOID ARTHRITIS; THERAPY EFFECT; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DRUG DESIGN; MEDICINAL CHEMISTRY; MEDICINAL PLANT; PATENT; PROCEDURES;

ANIMALS; BERBERINE; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HUMANS; MEDICINE, CHINESE TRADITIONAL; PATENTS AS TOPIC; PLANTS, MEDICINAL;

EID: 84957426918     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2016.1118060     Document Type: Article

References (110)

1. Grycova L, Dostal J, Marek R. Quaternary protoberberine alkaloids. Phytochemistry. 2007; 68: 150-175.
2. Hara Y, Suga C. Method for producing secondary metabolites of plants. US4717664. 1988.
3. Chen AH, Lee YT, Chen CY. Microwave accelerated extraction and capillary electrophoresis analysis of berberine from the cortices of Phellodendron wilsonii and Phellodendron amurense. J Chin Chem Soc. 2005; 52: 781-784.
4. Pecorelli I, Galarini R, Bibi R., et al. Simultaneous determination of 13 quinolones from feeds using accelerated solvent extraction and liquid chromatography. Analytica Chimica Acta. 2003; 483: 81-89.
5. Singh IP, Mahajan S. Berberine and its derivatives: a patent review (2009-2012). Expert Opin Ther Pat. 2013; 23: 215-231.
6. Liang KW, Yin SC, Ting CT., et al. Berberine inhibits platelet-derived growth factor-induced growth and migration partly through an AMPK-dependent pathway in vascular smooth muscle cells. Eur J Pharmacol. 2008; 590: 343-354.
7. Land H, McMurray HR, Sampson ER. Methods and compositions related to synergistic responses to oncogenic mutations. US20120114670. 2012.
8. Chung JG, Wu LT, Chu CB., et al. Effects of berberine on arylamine N-Acetyltransferase activity in human bladder tumour cells. Food Chem Toxicol. 1999; 37: 319-326.
9. Lin JG, Chung JG, Wu LT., et al. Effects of berberine on arylamine N-Acetyltransferase activity in human colon tumor cells. Am J Chin Med. 1999; 27: 265-275.
10. Wang DY, Yeh CC, Lee JH., et al Berberine inhibited arylamine N-Acetyltransferase activity and gene expression and DNA adduct formation in human malignant astrocytoma (G9T/VGH) and brain glioblastoma multiforms (GBM 8401) cells. Neurochem Res. 2002; 27: 883-889.
11. Lin SS, Chung JG, Lin JP., et al. Berberine inhibits arylamine N-Acetyltransferase activity and gene expression in mouse leukemia L 1210 cells. Phytomedicine. 2005; 12: 351-358.
12. Qin Y, Pang JY, Chen WH., et al. Inhibition of DNA topoisomerase I by natural and synthetic mono-And dimeric protoberberine alkaloids. Chem Biodivers. 2007; 4: 481-487.
13. Serafim TL, Oliveira PJ, Sardao VA., et al. Different concentrations of berberine result in distinct cellular localization patterns and cell cycle effects in a melanoma cell line. Cancer Chemother Pharmacol. 2008; 61: 1007-1018.
14. Kiyosuke Y, Tsuduki T, Shirakami T., et al. Berberine derivates for inhibiting hsp27 production. EP0813872A1. 1997.
15. Thor A, Benz C, Moore D., et al. Stress response protein (srp-27) determination in primary human breast carcinomas: clinical, histologic, and prognostic correlations. J Natl Cancer Inst. 1991; 83: 170-178.
16. Harrison JD, Jones JA, Ellis IO., et al. Oestrogen receptor D5 antibody is an independent negative prognostic factor in gastric cancer. Br J Surg. 1991; 78: 334-336.
17. Hm H, Cy L, Cc S., et al. Berberine-containing pharmaceutical composition for inhibiting cancer stem cell growth or carcinoma metastasis and application thereof. US20120321726. 2012.
18. Maung TW. Berberine as a selective lung cancer agent. US20070298132. 2007.
19. Lei H, Cao Y, Wang P., et al. Antitumor medicament. CN102659777A. 2012.
20. Huang Z, Gu L, Zhang W., et al. 9-Aminoalkyl chain substituted berberine derivation, preparation method, and the application as anticancer agent. CN101050213A. 2007.
21. Endo T, Ikeda Y, Ikekawa T., et al. Derivatives of berberine. US3884911. 1973.
22. Sawa Y. Novel berberine derivatives. US4033966. 1975.
23. Yu L, Hu LH, Zl L. Application of 8-diethyl malonate berberine in preparation of antitumor drug. CN103127101A. 2013.
24. Yu L, Liu ZL, Hu LH. Application of 8-propyl dicyan berberine in preparation of antitumor drug. CN103127102A. 2013.
25. Wu F, Li J, Li JY., et al. 8,8-Disubstituted-13,13a-dihyrdroberberine derivative as well as pharmaceutical composition and application thereof. CN101870694A. 2012.
26. Fan WZ, Wu XA, Mei XL., et al. Usage of berberine or derivatives thereof in preparation of tumor diagnosis imaging agent. CN102989017B. 2014.
27. Bashar AA, Hossan MS, Jahan R., et al. Berberine: a potential therapeutic candidate for breast cancer. J Pharm Pharm Sci. 2014; 3: 1858-1869.
28. Wang H, Lyu X, Lu D., et al. Application of berberine and doxorubicin mixed preparation in preparation of medicament against doxorubicin cardiac dysfunction and tumor. CN102008495. 2011.
29. Gu WW, Wang Y, Cheng T. Application of berberine combined chemotherapeutic medicament in antitumor therapy. CN103372210A. 2013.
30. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010; 70: 440-446.
31. Preparation method for Sanhuang tablet. CN103520294A. 2014.
32. Lee S, Lim HJ, Park JH., et al. Berberine-induced LDLR up-regulation involves JNK pathway. Biochem Biophys Res Commun. 2007; 362: 853-857.
33. Huang C, Zhang Y, Gong Z., et al. Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARgamma pathway. Biochem Biophys Res Commun. 2006; 348: 571-578.
34. Choi BH, Ahn IS, Kim YH., et al. Berberine reduces the expression of adipogenic enzymes and inflammatory molecules of 3T3-L1 adipocyte. Exp Mol Med. 2006; 38: 599-605.
35. Ning G, Wang N, Zhou L., et al. The application of berberine in pharmacy. CN103040821A. 2013.
36. Winder WW, Hardie DG. AMP-Activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol. 1999; 277: E1-10.
37. Kim WS, Lee YS, Cha SH., et al. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab. 2009; 296: E812-9.
38. Chen Z, Sun W. An antiobesity agent formed by -ricinoleic acid ethyl ester and berberine. CN101879162A. 2010.
39. Singh R, Kaushik S, Wang Y., et al. Autophagy regulates lipid metabolism. Nature. 2009; 458: 1131-1135.
40. Kim KH, Jeong YT, Oh H., et al. Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat Med. 2013; 19: 83-92.
41. Wang N, Feng Y, Zhu M., et al. Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism. J Cell Biochem. 2010; 111: 1426-1436.
42. Ning G, Zhang XY, Yang Y. Application of berberine in preparation of drugs inhibiting adipocyte autophagy. CN103393679A. 2013.
43. Deng Y, Xu J, Zhang X., et al. Berberine attenuates autophagy in adipocytes by targeting BECN1. Autophagy. 2014; 10: 1776-1786.
44. Ning G, Li B, Li XY., et al. Application of berberine in medicine for treating non-Alcoholic fatty liver disease. CN103393680A. 2013.
45. Liu Y, Zhang L, Song H., et al. Update on berberine in nonalcoholic fatty liver disease. Evid Based Complement Alternat Med. 2013; 2013: 308134.
46. Zhao HL, Sui Y, Qiao CF., et al. Sustained antidiabetic effects of a berberine-containing Chinese herbal medicine through regulation of hepatic gene expression. Diabetes. 2012; 61: 933-943.
47. Zhang X, Zhao Y, Zhang M., et al. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One. 2012; 7: e42529.
48. Jayaprakasam B, Olson LK, Schutzki RE., et al. Amelioration of obesity and glucose intolerance in high-fat-fed C57BL/6 mice by anthocyanins and ursolic acid in cornelian cherry (Cornus mas). J Agric Food Chem. 2006; 54: 243-248.
49. Matsui T, Ueda T, Oki T., et al. -Glucosidase inhibitory action of natural acylated anthocyanins. 1. Survey of natural pigments with potent inhibitory activity. J Agric Food Chem. 2001; 49: 1948-1951.
50. Zhang H, Wei J, Xue R., et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism. 2010; 59: 285-292.
51. Ni YC. Therapeutic effect of berberine on 60 patients with type II diabetes mellitus and experimental research. Zhong Xi Yi Jie He Za Zhi. 1988; 12: 711-713.
52. Ho J, Leung AK, Rabi D. Hypoglycemic agents in the management of type 2 diabetes mellitus. Recent Pat Endocr Metab Immune Drug Discov. 2011; 5: 66-73.
53. El-Kaissi S, Sherbeeni S. Pharmacological management of type 2 diabetes mellitus: an update. Curr Diabetes Rev. 2011; 7: 392-405.
54. Young J. Method of treating non-insulin dependent diabetes mellitus and related complications. US20100292178. 2010.
55. Gao CR, Zhang JQ, Huang QL. Experimental study on berberin raised insulin sensitivity in insulin resistance rat models. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1997; 17: 162-164.
56. Wu Y, Hai L, Wu JB., et al. Berberrubine 12-site derivatives as well as preparation method and applications thereof. CN102850346A. 2013.
57. Li R, Wu J, He Y., et al. Synthesis and in vitro evaluation of 12-(substituted aminomethyl) berberrubine derivatives as anti-diabetics. Bioorg Med Chem Lett. 2014; 24: 1762-1765.
58. Lei LN, Chen R, Li PY., et al. -Glycosidase inhibitor preparation method and purpose. CN103159755A. 2013.
59. Li WM, Yuan X, Rong XL., et al. One kind of polynuclear molecular compounds, their preparation and usage. CN103709157A. 2014.
60. Hundal RS, Petersen KF, Mayerson AB., et al Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest. 2002; 109: 1321-1326.
61. Peng DM, Liao DF, Xie MJ., et al. Acetylsalicylic acid berberine salt, preparation method and application thereof. CN103204850A. 2013.
62. Ji Y, Zhou K, Su XY., et al. Oral medicine composition consisting of berberine and melbine, and preparation method thereof. CN103271907A. 2014.
63. Gu L, Li N, Gong J., et al. Berberine ameliorates intestinal epithelial tight-junction damage and down-regulates myosin light chain kinase pathways in a mouse model of endotoxinemia. J Infect Dis. 2011; 203: 1602-1612.
64. Zhang Q. Pharmaceutical composition for the treatment of pelvic inflammation. CN102302505. 2012.
65. Wang B, Fang W, Yan F., et al. Application of berberine to preparing drug for preventing and treating familial adenomatous polyposis. CN102058590. 2011.
66. Jeong HW, Hsu KC, Lee JW., et al. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab. 2009; 296: E955-64.
67. Jiang Q, Liu P, Wu X., et al. Berberine attenuates lipopolysaccharide-induced extracellular matrix accumulation and inflammation in rat mesangial cells: involvement of NF-kappaB signaling pathway. Mol Cell Endocrinol. 2011; 331: 34-40.
68. Yao J, Kong W, Jiang J. Learning from berberine: treating chronic diseases through multiple targets. Sci China Life Sci. 2013; 56: 1-6.
69. Meng S, Wang LS, Huang ZQ., et al. Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention. Clin Exp Pharmacol Physiol. 2012; 39: 406-411.
70. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004; 27: 813-823.
71. Yan F, Wang L, Shi Y., et al. Berberine promotes recovery of colitis and inhibits inflammatory responses in colonic macrophages and epithelial cells in DSS-treated mice. Am J Physiol Gastrointest Liver Physiol. 2012; 302: G504-14.
72. Jiang YH. Applications of berberine in preparation of medicines used for treating ulcerative colitis. CN103830234. 2014.
73. Peng DM, Liao DF, Ding JH., et al. Preparation method and application of substituted aryl propionic berberine ion-pair compound. CN103193772A. 2013.
74. Lu DY, Tang CH, Chen YH., et al. Berberine suppresses neuroinflammatory responses through AMP-Activated protein kinase activation in BV-2 microglia. J Cell Biochem. 2010; 110: 697-705.
75. Theoharis CT. Anti-inflammatory compositions for treating neuro-inflammation. WO2014046700A1. 2014.
76. Jiang J, Kong W, Zhao L., et al. Methods and compositions for the treatment of hyperlipidemia. WO2006029577A1. 2006.
77. Wang C, Huang Z, Wang L., et al. Application of berberine in preventing and treating atherosclerosis. CN101627995A. 2010.
78. Liu H, Li G, Wang J., et al. Berberine derivatives useful for modulating lipid levels and their methods of synthesis. WO2011006000A1. 2011.
79. Wang CQ, Meng S, Cao JT. Application of berberine derivative in preparation of drug for treating atherosclerosis. CN103804374A. 2014.
80. Boche D, Zotova E, Weller RO., et al. Consequence of Abeta immunization on the vasculature of human Alzheimers disease brain. Brain. 2008; 131: 3299-3310.
81. Griffiths HH, Morten IJ, Hooper NM. Emerging and potential therapies for Alzheimers disease. Expert Opin Ther Targets. 2008; 12: 693-704.
82. Lukiw WJ. Emerging amyloid beta (A beta) peptide modulators for the treatment of Alzheimers disease (AD). Expert Opin Emerg Drugs. 2008; 13: 255-271.
83. Kong W, Wei J, Abidi P., et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004; 10: 1344-1351.
84. Ye MZ, Fu S, Pi RB., et al. Neuropharmacological and pharmacokinetic properties of berberine: a review of recent research. J Pharm Pharmacol. 2009; 61: 831-837.
85. Ji HF, Shen L. Berberine: a potential multipotent natural product to combat Alzheimers disease. Molecules. 2011; 16: 6732-6740.
86. Kulkarni SK, Dhir A. Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders. Phytother Res. 2010; 24: 317-324.
87. Yang Q, Yu C, Kuang C., et al. Application of berberine and derivatives thereof in preparation of indole amine 2, 3-dioxygenase inhibitor. CN101843618A. 2010.
88. Teng H, Wu W. Mangiferin-berberine salt, manufacturing method and use thereof. WO2010145192A1. 2010.
89. Durairajan SS, Liu LF, Lu JH., et al. Berberine ameliorates beta-Amyloid pathology, gliosis, and cognitive impairment in an Alzheimers disease transgenic mouse model. Neurobiol Aging. 2012; 33: 2903-2919.
90. Li M, Durairajan SSK, Liu LF., et al. Berberine alkaloid as a medicament for prevention and treatment of neural disease. US20130237556A1. 2013.
91. Fernandes RA, Ingle AB. Arundic acid a potential neuroprotective agent: biological development and syntheses. Curr Med Chem. 2013; 20: 2315-2329.
92. Aplin AE, Gibb GM, Jacobsen JS., et al. In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta. J Neurochem. 1996; 67: 699-707.
93. Teng HL, Wu W. Mangiferin-berberine salt, manufacturing method and use thereof. US8673864B2. 2014.
94. Gao JL, Shi JM, Lee SM., et al. Angiogenic pathway inhibition of Corydalis yanhusuo and berberine in human umbilical vein endothelial cells. Oncol Res. 2009; 17: 519-526.
95. Shi Y, Sun H, Jin W., et al. Protoberberine quaternary ammonium base composition and use thereof. CN103284998A.(2013.
96. Ro DK, Paradise EM, Ouellet M., et al. Production of the antimalarial drug precursor artemisinic acid in engineered yeast. Nature. 2006; 440: 940-943.
97. Elizabeth AW, Micah JM. Drug resistance genomics of the antimalarial drug artemisinin. Genome Biol. 2014; 15: 544.
98. Rosen B, Muehler A, Mintorovitch J., et al. Artemisinin and berberine compositions and methods of making. WO2013063271A1. 2013.
99. Kim MH, Choi YY, Yang G., et al. Indirubin, a purple 3,2-bisindole, inhibited allergic contact dermatitis via regulating T helper (Th)-mediated immune system in DNCB-induced model. J Ethnopharmacol. 2013; 145: 214-219.
100. Lin YK, Leu YL, Yang SH., et al. Anti-psoriatic effects of indigo naturalis on the proliferation and differentiation of keratinocytes with indirubin as the active component. J Dermatol Sci. 2009; 54: 168-174.
101. Chantalat L, Andres P. Combinations of indigo naturalis and berberine and uses thereof, WO2014130638A1.(2014.
102. Patani GA, LaVoie EJ. Bioisosterism: a rational approach in drug design. Chem Rev. 1996; 96: 3147-3176.
103. Iwasa K, Moriyasu M, Yamori T., et al. In vitro cytotoxicity of the protoberberine-type alkaloids. J Nat Prod. 2001; 64: 896-898.
104. Kobayashi Y, Yamashita Y, Fujii N., et al. Inhibitors of DNA topoisomerase I and II isolated from the Coptis rhizomes. Planta Med. 1995; 61: 414-418.
105. Ma Y, Ou TM, Hou JQ., et al. 9-N-substituted berberine derivatives: stabilization of G-quadruplex DNA and down-regulation of oncogene c-myc. Bioorg Med Chem. 2008; 16: 7582-7591.
106. Jin Y, Khadka DB, Yang SH., et al. Synthesis of novel 5-oxaprotoberberines as bioisosteres of protoberberines. Tetrahedron Lett. 2014; 55: 1366-1369.
107. Cheng K, Rahier NJ, Eisenhauer BM., et al. 14-Azacamptothecin: a potent water-soluble topoisomerase I poison. J Am Chem Soc. 2005; 127: 838-839.
108. Bauer A, Bronstrup M. Industrial natural product chemistry for drug discovery and development. Nat Prod Rep. 2014; 31: 35-60.
109. Tobis JM, Aronow WS. Cardiotoxicity of amitriptyline and doxepin. Clin Pharmacol Ther. 1981; 29: 359-364.
110. Makheya D, Yub C, Liu A., et al. Substituted benz[a]acridines and benz[c]acridines as mammalian topoisomerase poisons. Bioorg Med Chem. 2000; 8: 1171-1182.